Published in J Cancer Res Clin Oncol on January 01, 1991
Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol (1998) 2.22
EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics (1998) 1.49
Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology (1995) 1.46
Halobacterial glycoprotein saccharides contain covalently linked sulphate. FEBS Lett (1980) 1.36
Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood (2000) 1.19
Interaction of poliovirus with its cell surface binding site. Virology (1994) 1.16
Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal Biochem (1990) 1.13
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol (1992) 1.11
Downstream activation of a TATA-less promoter by Oct-2, Bob1, and NF-kappaB directs expression of the homing receptor BLR1 to mature B cells. J Biol Chem (1998) 1.11
Comparison of the serology, transforming ability, and polypeptide composition of human papovaviruses isolated from urine. J Virol (1976) 1.04
Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol (1992) 1.02
The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin. Virology (2001) 1.02
Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. J Biol Chem (2000) 1.01
Pressure-Induced Alterations in the Protein Pattern of the Thermophilic Archaebacterium Methanococcus thermolithotrophicus. Appl Environ Microbiol (1988) 0.95
The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. Biochem Biophys Res Commun (2007) 0.95
Structural characterization of glycoprotein carbohydrate chains by using diagoxigenin-labeled lectins on blots. Anal Biochem (1990) 0.94
Trans-activation of human MYC: the second promoter is target for the stimulation by adenovirus E1a proteins. Oncogene (1989) 0.93
Antispasmodic activity of Thymus vulgaris extract on the isolated guinea-pig trachea: discrimination between drug and ethanol effects. Planta Med (1999) 0.92
Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy. Cancer Lett (1998) 0.91
The promoters for human and monkey poliovirus receptors. Requirements for basic and cell type-specific activity. J Biol Chem (1997) 0.90
Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2 -diphenylethanes. J Med Chem (1980) 0.86
Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett (1998) 0.86
Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers. Cancer Lett (1998) 0.85
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma. J Med Chem (1988) 0.85
Identification and characterization of the cis-acting elements of the human CD155 gene core promoter. J Biol Chem (1999) 0.85
[Antimicrobial and tumor-inhibiting properties of dithiourethane and studies on the mechanism of action. 16. Cytostatica]. Pharmazie (1972) 0.85
Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol (1995) 0.84
Cleavage site of the poliovirus receptor signal sequence. J Gen Virol (1994) 0.84
Analyzing cytotoxic T lymphocyte activity: a simple and reliable flow cytometry-based assay. J Immunol Methods (1997) 0.83
Programmable biodegradable implants. J Control Release (2001) 0.83
Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1). Virchows Arch B Cell Pathol Incl Mol Pathol (1992) 0.82
Poliovirus and its cellular receptor: a molecular genetic dissection of a virus/receptor affinity interaction. J Mol Recognit (1998) 0.82
A lymphoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. Curr Top Microbiol Immunol (1999) 0.82
Platinum compounds with estrogen receptor affinity. Cancer Treat Rev (1990) 0.81
Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice. Cancer Chemother Pharmacol (1996) 0.81
The human poliovirus receptor alpha is a serine phosphoprotein. J Virol (1994) 0.80
Cloning and functional expression of the hNPY Y5 receptor in human endometrial cancer (HEC-1B) cells. Can J Physiol Pharmacol (2000) 0.80
1,1,2-triphenylbut-1-enes: relationship between structure, estradiol receptor affinity, and mammary tumor inhibiting properties. J Med Chem (1982) 0.80
Reassociation of lactic dehydrogenase from pig heart studied by cross-linking with glutaraldehyde. Z Naturforsch C (1982) 0.79
Molecular determinants for the high constitutive activity of the human histamine H4 receptor: functional studies on orthologues and mutants. Br J Pharmacol (2014) 0.79
The human poliovirus receptor. Receptor-virus interaction and parameters of disease specificity. Ann N Y Acad Sci (1995) 0.79
Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part II--The antileukemic effect. Arch Pharm (Weinheim) (1989) 0.79
[The mode of local anesthetic action of cinchocaine homologues]. Arzneimittelforschung (1970) 0.78
[Synthesis of 14C-anpirtoline]. Arch Pharm (Weinheim) (1988) 0.78
Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226. Bioorg Med Chem Lett (2000) 0.78
A rapid luciferase transfection assay for transcription activation effects and stability control of estrogenic drugs in cell cultures. J Cancer Res Clin Oncol (1994) 0.78
Determinants of poliovirus neurovirulence. J Neurovirol (1997) 0.78
High-resolution reversed-phase high-performance liquid chromatography analysis of polyamines and their monoacetyl conjugates by fluorescence detection after derivatization with N-hydroxysuccinimidyl 6-quinolinyl carbamate. Anal Biochem (1997) 0.78
Mechanism of sucrose retrieval along the phloem path - a kinetic approach. Planta (1990) 0.78
Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted omega-guanidino- and omega-aminoalkanoic acid amides. Arch Pharm (Weinheim) (1997) 0.78
NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures. Regul Pept (1998) 0.78
Dichloro-[1-(hydroxyphenyl)-2-phenylethylenediamine]platinum(II) complexes: testing on the human ovarian cancer cell lines NIH: OVCAR3 and SK OV 3. Arch Pharm (Weinheim) (1992) 0.78
Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts. Int J Pharm (2002) 0.77
In vitro activity of immunoconjugates between cisplatin and an anti-CA125 monoclonal antibody on ovarian cancer cell lines. Cell Biophys (1994) 0.77
Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part I--The antibacterial effect. Arch Pharm (Weinheim) (1989) 0.77
Benzylamines: synthesis and evaluation of antimycobacterial properties. J Med Chem (1984) 0.77
Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines. Cancer Res (1991) 0.77
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer. J Cancer Res Clin Oncol (1993) 0.77
Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes. Arch Pharm (Weinheim) (1993) 0.76
[1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activity. Prostate (1989) 0.76
Computer modelling of estrogenic transcriptional activation can account for different types of dose-response curves of estrogens. J Steroid Biochem Mol Biol (1993) 0.76
N,N'-Dialkyl-1,2-bis(hydroxyphenyl)ethylenediamines and N,N-dialkyl-4,5-bis(4-hydroxyphenyl)imidazolidines: syntheses and evaluation of their mammary tumor inhibiting activity. J Med Chem (1982) 0.76
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative. J Cancer Res Clin Oncol (1998) 0.76
Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation. Cancer Chemother Pharmacol (1992) 0.76
[Development of new antiestrogens of the 3,3'-dihydroxy-alpha, beta-diethylstilbene-type and their evaluation on the DMBA-induced hormone dependent mammary carcinoma of the SD-rat (author's transl)]. J Cancer Res Clin Oncol (1980) 0.76
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity. Arch Pharm (Weinheim) (1995) 0.75
Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma. J Med Chem (1984) 0.75
[Studies on the mechanism of the reduction of Schiff bases with activated aluminum in ethyl alcohol. 6. On cytostatic agents]. Arch Pharm Ber Dtsch Pharm Ges (1967) 0.75
[Antineoplastic effect of N,N',N''-trihydroxymethylmelamine and analogous compounds. 23. Cytostatic agents]. Arch Pharm (Weinheim) (1973) 0.75
[The mode of action of local anesthetics. 7. Synthesis of enantiomeric N-aminoacyl-2.6.-dimethylaniline, -benzylamine and-2-phenylethylamine]. Pharmazie (1976) 0.75
Anticancer drugs: estrophilic cisplatin derivatives. Cancer Treat Rev (1987) 0.75
N,N'-Dialkylbis(dichlorophenyl)ethylenediamines and -imidazolidines: relationship between structure and estradiol receptor affinity. J Med Chem (1980) 0.75
[On the effect of N-aminoacylephedrines, a new class of local anesthetics. Attempts at the preparation of presser active local anesthetics]. Arzneimittelforschung (1967) 0.75
A simple method of delayed processing of tumor tissue in a soft agar clonogenic assay. J Cancer Res Clin Oncol (1988) 0.75
[Synthesis and tumor inhibiting effect of N-(bis(2-chlorethyl)-aminomethyl)-amides. 21. Cytostatic agents]. Arch Pharm (Weinheim) (1973) 0.75
[Effect of aminomethylating carcinostatics on experimental animal tumors. IV. On cytostatics]. Arzneimittelforschung (1966) 0.75
[Dimer exchange products of aromatic substituted alpha-aminonitriles. VII. Conversion of alpha-aminonitriles]. Arch Pharm Ber Dtsch Pharm Ges (1969) 0.75
[The action mechanisms of local anesthetics. 9. N-aminoacyl-beta-phenylalkylamine tested for development of antidepressive agents from psychotonics]. Pharmazie (1976) 0.75
[Synthesis and local anesthetic effect of N-piperidino-methyl-4-alkoxybenzamides]. Arch Pharm Ber Dtsch Pharm Ges (1970) 0.75
[Experimental chemotherapy of mammary neoplasms. A review]. Pharmazie (1976) 0.75
[Conversions of aliphatic substituted alpha-aminonitriles with metallic sodium in toluol. VI. Conversion of alpha-aminonitriles]. Arch Pharm Ber Dtsch Pharm Ges (1969) 0.75
[Intraocular lenses - aphorisms of an operating practitioner (author's transl)]. Klin Monbl Augenheilkd (1979) 0.75
[Studies on the mechanism of action of local anesthetics. 6. Binding of local anesthetics of complementary membranes structures]. Pharmazie (1972) 0.75
[The relationship between structure and tuberculostatic effect in the benzylamine group]. Pharmazie (1976) 0.75
Influence of ring substituents on the antitumor effect of dichloro(1,2-diphenylethylenediamine)platinum(II) complexes. J Cancer Res Clin Oncol (1988) 0.75
[Mechanistic studies on the formation of diphenylethylene-diamines from benzylidenealkylamines and activated aluminum. 5. On cytostatic agents]. Arch Pharm Ber Dtsch Pharm Ges (1967) 0.75
[Studies of mechanism of action on antimicrobically effective beta-aminoketones]. Pharm Acta Helv (1969) 0.75
[Relations between physical-chemical properties and antimicrobial effect of beta-amino-ketones. 9. Cytostatics]. Arzneimittelforschung (1970) 0.75
[Azomethines and oxazolidines from norfenefrine. Development of compounds with prolonged action and blood pressure increasing effect]. Arch Pharm (Weinheim) (1975) 0.75
[Mammary-tumor-inhibiting antiestrogens of the 3,3'-dihydroxy-alpha, beta-dialkylstilbene type (author's transl)]. Arch Pharm (Weinheim) (1980) 0.75
[The working mechanism of local anesthetics. 8. Preparation of enantiomer N-phthalylamino carbonic acids]. Pharmazie (1976) 0.75
[Antimycobacterial effect of N-alkylbenzylamines]. Pharmazie (1977) 0.75
[Reaction method of alpha-aminoacetonitrile with metallic sodium in liquid ammonia. 8. Conversion of alpha-aminonitriles]. Arch Pharm Ber Dtsch Pharm Ges (1969) 0.75
[Synthesis and pharmacological test of N-(3'-methoxy-benzamidomethyl)-D-norephedrine and Analogous Compounds (author's transl)]. Arch Pharm (Weinheim) (1976) 0.75